Hyperphosphorylated tau protein leads to cellular dysfunction and abnormal deposition in the brains of late-stage HD patients, highlighting its importance as a disease progression marker [133], suggesting that therapeutic strategies targeting tau protein may become a potential treatment for HD. This evidence concerns the gene MAPT and Huntington disease.